MINI FUTURE OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 01:19:41 01/06/2024 am IST | ||
| 13.37 EUR | -9.17% |
|
| 1 month | -31.15% | ||
| 3 months | -19.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 13.37 | -9.17% |
| 30/24/30 | 14.72 | -1.21% |
| 29/24/29 | 14.9 | +4.41% |
| 28/24/28 | 14.27 | +10.02% |
| 27/24/27 | 12.97 | -2.92% |
Delayed Quote Börse Stuttgart
Last update May 01, 2024 at 01:19 am IST
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB39C2 |
| ISIN | DE000JB39C27 |
| Date issued | 17/10/2023 |
| Strike | 601.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 21.71 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.74 € |
|---|---|
| Lowest since issue | 12.97 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Certificates
- Certificat
